课题基金 / 基金详情

Human Disease-Specific Induced Pluripotent Stem Cells For Preclinical Drug Testing and Drug Discovery

Human Disease-Specific Induced Pluripotent Stem Cells For Preclinical Drug Testing and Drug Discovery
用于临床前药物测试和药物发现的人类疾病特异性诱导多能干细胞
批准号:
10384967
负责人:
Lynne A Bui
金额:
$172.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-03-04 至 2023-02-28
关键词:
AddressAfrican American populationAreaArrhythmiaAsian populationBiological AssayBiological SciencesCalciumCalcium ChannelCardiacCardiotoxicityCardiovascular AgentsCardiovascular DiseasesCardiovascular systemCaucasiansCell LineCell NucleusCell SurvivalCellsChemicalsCisaprideClarithromycinClinicClinical TrialsCollaborationsCollectionCommunitiesDataDevelopmentDexrazoxaneDilated CardiomyopathyDiseaseDoseDoxorubicinDrug ExposureDrug IndustryDrug ScreeningDrug toxicityDyesEthnic OriginEthnic groupExposure toFailureFamilial Hypertrophic CardiomyopathyFemaleFiberGenderGeneticGenetic Predisposition to DiseaseHeart AbnormalitiesHeart DiseasesHispanic PopulationsHourHypertrophic CardiomyopathyHypertrophyIndividualIndustrializationInheritedInstitutesLabelLaboratoriesLibrariesLong QT SyndromeMedicalMetabolicMetoprololMexiletineMorbidity - disease rateMuscle CellsNifedipinePathologicPatientsPersonsPharmaceutical PreparationsPharmacologic SubstancePharmacologyPhenotypePopulationPopulation HeterogeneityPredispositionProcessProtocols documentationResearch Project GrantsRightsRiskRisk FactorsSafetyServicesSmall Business Innovation Research GrantSotalolStressStructural defectTamoxifenTechnologyTestingTimeToxicity TestsTranslatingUniversitiesVerapamilWithdrawalWomanWorkbasecardioprotectionchronotropiccohortcostdofetilidedrug candidatedrug developmentdrug discoverydrug marketdrug testingelectric impedanceethnic diversitygender diversityhigh riskhuman diseasein vitro Modelinduced pluripotent stem cellinnovationmalemembermenmortalitynovel therapeuticspatient populationpre-clinicalpredictive modelingprotective effectracial diversityranolazineresazurinresponsescreeningsextool

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
摘要 药物引起的心脏不良反应是药物消耗的主要原因 发展。近年来,几种心脏和非心脏药物因 不可预测的心脏毒性给制药业带来了数十亿美元的负担。结果, FDA现在要求所有新药在进入临床试验之前都要进行心脏毒性测试。然而,在那里 仍然缺乏适当的安全筛查平台来准确预测心律失常的易感性 新的化学实体;特别是没有经过验证的商业平台来解决多样化的 患者群体的性别、种族或对药物引起的心脏毒性的遗传易感性。 该公司正在开发一种精选的50种细胞系,这些细胞系来自健康受试者和患者 常见遗传性心脏病,如家族性肥厚型心肌病(HCM),扩张型 心肌病(DCM)和长QT综合征(LQTS),以预测个人和组在药物方面的差异 对心脏毒性的敏感性。因为女性是药物所致心律失常的独立危险因素 而女性占人口的50%以上,这项研究项目的一个主要重点将是量化 性别因素在药物性心律失常中的程度。每个细胞系都将被验证为具有功能和 从药理上讲。这组细胞系在广度和细节方面将是独一无二的(匿名) 每条线路的患者和基因数据。虽然一些相互竞争的公司只有一条或两条线路,但它们不会 执行服务,不包括Khloris可获得的详细患者和基因数据。 Khloris Biosciences是一家总部位于旧金山湾区的初创公司。科洛里斯是由约瑟夫博士共同创立的。 吴(斯坦福大学),并拥有世界上最大的患者来源集合的全球独家权利 在他的实验室开发的IPSC-CMS以及匿名的遗传和病理特征 每一行。 当前SBIR应用程序的目的是极大地扩展Khloris的当前产品,使其包括 大量多样的有效细胞系,包括男性和女性衍生的疾病特异性IPSC- 来自常见遗传性心脏病患者的CMS和遗传背景。我们的目标是开发和 验证该工具作为预测高危患者组心脏药物毒性的体外模型的替代性 用于药物引起的心律失常。Khloris相信,这个平台将通过以下方式使药物发现和开发发生革命性变化 重新分配心脏毒性的阈值,从而降低错误地消除前景的可能性 加速有价值的药物进入临床并发现新的心血管药物。
英文摘要
ABSTRACT Drug-induced adverse cardiac effects are a leading cause of drug attrition during pharmaceutical development. In recent years, the withdrawal of several cardiac and non-cardiac drugs from the market due to unpredicted cardiotoxicity has imposed a multibillion-dollar burden on the pharmaceutical industry. As a result, FDA now mandates that all new drugs be tested for cardiotoxicity before entering clinical trials. However, there is still a lack of appropriate safety screening platforms that can accurately predict the proarrhythmic liability of new chemical entities; in particular there are no validated commercial platforms that address the diverse patient population with regard to sex, ethnicity or genetic susceptibility to drug-induced cardiotoxicity. The company is developing a select subset of fifty cell lines from healthy subjects as well as from patients with common hereditary cardiac disorders such as familial hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and long QT syndrome (LQTS), to predict individual and group differences in drug susceptibility to cardiotoxicity. As female sex is an independent risk factor for drug-induced cardiac arrhythmias and women comprise more than 50% of the population, a major focus of this research project will be to quantify the extent gender factors in drug-induced proarrhythmia. Each cell line will be validated functional and pharmacologically. This panel of cell lines will be unique in terms of its breadth and detailed (anonymized) patient and genetic data for each line. While some competing companies cell one or two lines, they do not perform services and do not include the detailed patient and genetic data available to Khloris. Khloris Biosciences is a start-up company based in the Bay Area. Khloris was co-founded by Dr. Joseph Wu (Stanford University) and has worldwide exclusive rights to the world’s largest collection of patient-derived iPSC-CMs developed in his laboratory as well as the anonymized genetic and pathological characterization of each line. The purpose of the current SBIR application is to greatly expand the current offering of Khloris to include a large and diverse collection of validated cell lines comprising male AND female derived disease-specific iPSC- CMs from patients with common hereditary cardiac disorders and genetic backgrounds. We aim to develop and validate this tool as a surrogate in vitro model for prediction of cardiac drug toxicity in patient groups at high risk for drug-induced arrhythmia. Khloris believes this platform will revolutionize drug discovery and development by reassigning the thresholds for cardiotoxicity, thereby reducing the possibility of mistakenly eliminating promising candidates, expediting the advancement of worthy drugs to clinic and discovering new cardiovascular drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金